EventsThe 4th International Electronic Conference on Antibiotics
Published
This submission belongs to the session S4. Novel Antimicrobial Agents: Discovery, Design, Synthesis and Action of the event The 4th International Electronic Conference on Antibiotics
Published date
19 May, 2025
Academic Editor
author-avatarJordi Vila
Citation
Anita Bułakowska, Jarosław Sławiński, Yahor Ivashchanka, Rafał Hałasa, Antimicrobial activity evaluation of N-(aryl/heteroaryl)-2-chlorobenzenesulfonamide derivatives, in Proceedings of The 4th International Electronic Conference on Antibiotics, 21 May–23 May 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Antimicrobial activity evaluation of N-(aryl/heteroaryl)-2-chlorobenzenesulfonamide derivatives

image
1. Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland, Poland
2. Faculty of Pharmacy, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland, Poland
3. Department of Pharmaceutical Microbiology, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland, Poland
Abstract

Antibiotic resistance is currently a global problem for modern civilization. Microorganisms become resistant to drugs through acquired mechanisms. Six pathogens are responsible for the majority of deaths: Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Growing drug resistance makes basic antibiotic therapy ineffective and increases the costs of polytherapy [1]. In recent years, there has been increasing interest in organic compounds that contain an aryl or a heteroarylsulfonamide group in their structure, which are characterized not only by anticancer activity but also by antimicrobial activity [2]. The presented studies follow the trend of searching for new hybrid molecules resulting from the combination of different pharmacophores with interesting biological profiles.

The antibacterial activity of compounds that had previously shown interesting anticancer activity was assessed [3]. The compounds were subjected to an assessment of their antibacterial activity in in vitro tests against the Gram-positive bacterium Staphylococcus aureus (MIC = 8 µg/mL) and the Gram-negative Escherichia coli (MIC > 125 µg/mL). The most active derivative (16) was tested against the Gram-positive bacteria S. epimermidis, E. faecalis, and B. subtilis (MICs in a range from 2 to 125 µg/mL) and clinical strains of MRSA (MICs between 0.5 and 1 µg/mL). Ampicillin was used as the standard. The activity of the tested compound against a bacterial biofilm was also tested, and its hemolytic activity was assessed in the peripheral blood of domestic sheep.

References:

    [1] Uddin T. M., Chakraborty A. J., Khusro A., Zidan R. M., Mitra S., Emran T. B., Dhama K., Ripon K. H., Gajdács M., Sahibzada M. U. K., Hossain J.; J. Infect. Public Health (2021), 14 (12), 1750.

    [2] Verma S. K., Verma R., Xue F., Thakur P. K., Girish Y. R., Rakesh K. P.; Bioorg. Chem. (2020), 105, 104400.

    [3] Bułakowska A., Sławiński J., Siedlecka-Kroplewska K., Stasiłojć G., Serocki M., Heldt M., Bioorg. Chem. (2020), 104, 10430.

      Keywords
      Organic Synthesis Antitumor Agents Antibacterials Cytotoxicity
      Poster
      Poster_Anita Bułakowska.pdf
      Antibiotic producers associated with the bark beetle Ips typographus
      Targeting Biofilm-Associated Infections: Antimicrobial and Antibiofilm Effects of Biogenic Zinc Nanoparticles